Countries China

WuXi AppTec Triples Peptide Capacity, Launches Taixing API Site

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech an...

 January 09, 2024 | News

The pioneering clinical implementation of Base Editing Therapy for Hemoglobinopathy on a global scale

On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE...

 January 09, 2024 | News

OBI Pharma's partner Biosion announces FDA clearance for the Phase 1/2 study of OBI-992 (TROP2 ADC)

First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...

 January 09, 2024 | News

Akeso's Cadonilimab Granted NMPA Acceptance for First-Line Gastric Cancer Treatment.

This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...

 January 08, 2024 | News

Kexing Biopharm Expands Global Portfolio with Eribulin Mesylate Injection

Eribulin Mesylate Injection is indicated for patients with locally advanced or metastatic breast cancer who have undergone at least two chemotherapy r...

 January 08, 2024 | News

Belief BioMed Completes First Dosing in Hemophilia A Trial

BBM-H803 is Belief BioMed's first gene therapy for the treatment of hemophilia A and is the company's second product which has obtained IND approval from t...

 January 04, 2024 | News

WuXi XDC Partners with IntoCell to Boost ADC Discovery and Development

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...

 January 03, 2024 | News

MediLink Therapeutics Partners with Roche for Oncology Antibody Drug Conjugate

Under the terms of the agreement, MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's...

 January 03, 2024 | News

Biocytogen, CtM Bio Make Strides in TCR-Mimic Antibody Development

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd ("CtM Bio") jointly announce tha...

 January 01, 2024 | News

Clover's SCB-219M Shows Positive Phase I Results for Chemotherapy-Induced Thrombocytopenia (CIT) Treatment

--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...

 December 29, 2023 | News

RemeGen's RC88 Granted FDA IND Approval for Platinum-Resistant Ovarian Cancer

  The open-label, randomized, dose optimization phase 2 study aims to enroll participants in multiple countries to further clarify the optimal dosage...

 December 29, 2023 | News

Innovent and Xuanzhu Collaborate on Clinical Trial for Combined Therapy in Chinese Solid Tumor Treatment

Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical stud...

 December 29, 2023 | News

PharmaBlock Sciences Unveils State-of-the-Art High Potency API Facility in Zhejiang Site.

The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1...

 December 28, 2023 | News

FDA Grants Orphan Drug Designation to Boan Biotech's Two Novel Claudin 18.2 Drugs.

Orphan drugs, also known as drugs for rare diseases, are drugs for preventing, treating or diagnosing rare diseases. Being designated as orphan drugs will ...

 December 28, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in